An average of 35% of patients diagnosed with Parkinson’s disease experience Parkinson’s psychosis. Recognition and diagnosis of this nonmotor manifestation is critical in choosing the best treatment strategy and managing these symptoms.
Antipsychotics can be used in the short-term to manage dementia-related psychosis, but serious adverse effects can outweigh benefits. Novel antipsychotics or other agents may offer superior efficacy and safety. Explore the evidence in this CME activity.
In this CME activity, listen to a panel of MDD experts discuss best practices and novel antidepressants at the 2019 ASCP Annual Meeting.
What are the cardinal features of Parkinson disease? What other motor and nonmotor symptoms do patients experience? Review diagnosis and assessment tools.
Which medications can improve the motor and nonmotor symptoms of Parkinson disease? Dr Isaacson offers strategies to address multiple challenges.
Learn which symptoms of psychosis are common in different types of dementia and how to compassionately discuss them with patients and their care partners.


LAI antipsychotics can improve adherence but are underused. Hear interviews with patients and learn from experts how LAIs may translate into clinical benefit.


Do you talk with your patients with Parkinson disease about the burden of OFF episodes? Using assessment tools can spur communication. In this CME activity, follow along as 2 experts review the occurrence and identification of OFF time.
After several years, patients with Parkinson disease often experience OFF episodes, or periods each day when medication efficacy “wears off.” How can you increase their ON time? In this CME activity, follow along as 2 experts review evidence on treatment.
Subscribe to RSS - Parkinson Disease